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Phensic tablets have not contained phenacetin since 1966 (1976). Phenacetin
was first introduced in 1887 but it was not until 1953 that suspicion was aroused
that it might cause renal damage (Lawrence, 1973). There is only circumstantial
evidence for this, but it has become so strong that in the United States of America
it is compulsory for a warning label to be displayed on all preparations sold to the
public. In Sweden it has to be sold on prescription only, and in Great Britain
"The Medicines (Phenacetin Prohibition) Order 1974" prohibited the sale of
phenacetin-containing compounds except on prescription, because, if used regu-
larly, it could cause renal damage (Prescribers Journal, 1974). Currently, the
tablet of Phensic contains aspirin 380 mgm, salicylamide 30 mgm, caffeine 16
mgm (Martindale, 1972).
A CASE REPORT
A 37-year-old married woman, who worked in a bakery, presented with a
history of severe headaches and inexhaustible energy. She was happily married
with one daughter, aged 5 years. After careful questioning she reluctantly
admitted that she had been taking an average of 14 tablets of Phensic per day for
6 years. She looked healthy, appeared happy but agitated. The heart was normal,
pulse 82 and regular, and the blood pressure was 110/70mm/Hg. All other systems
including optic discs were normal. She was taking Ovulan 50.
Investigations
Blood count, thyroid function, sedimentation rate, plasma protein levels and
urine analyses were normal. Serum bilirubin 54.4. umol/I (normal range 1-17)
and liver enzymes including alkaline phosphatase 886 IU/1 (normal range 115-
320), asparate transaminase 307 IU/1 (normal range 5-40), alamine transaminase
605 IU/1 (normal range 5-50), gamma glutmyl transpepitase 140 IU/1 (normal
range 5-50)10-45), cholinesterase 2220 IU/1 (normal range 2000-500) were greatly
elevated. The blood urea was 12 mmol/1 (normalrange 2.3-6.6).
(Dr. J. N. Brown) "There is no intra-renal calcification. The kidneys are
normal in size and outline. There is no opacification of the renal papillae through-
out, due to contrast in the distal tubule. This (pyelotubular reflux) can be seen in
normal people, but it is unusual to be seen to this extent and particularly in the
film without compression. It is felt that the appearances described are likely to be
a result of her phenacetin intake, and probably reflects some change in the renal
papillae prior to the necrosis of a fully developed case."
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The patient was warned of the damage done to kidneys and liver, and of the
dangers if the addiction was allowed to continue. She was given diazepam 5 mgm
three times a day for the expected withdrawal symptoms and fluazepam 30 mgm
for the insomnia. She was seen regularly so that the withdrawal period was closely
scrutinised, and she was extremely co-operative. She made excellent progress and
one month later the liver function tests had returned to normal and the blood urea
was 4.6 mmol/l. On the advice of the consultant radiologist an intravenous
pyelogram was carried out after six months and he reported that there was no
change in the appearance of the renal papillae. The patient is still being
reviewed after nine months and remains well and free from addiction.
COMMENT
Phenacetin was introduced in 1887 and until 1953 it was not thought to have
any serious effects. Since then many observers have tended to incriminate it as
causing renal papillary necrosis as well as certain blood dyscrasias. All the evidence
so far tends to be circumstantial because in animal studies phenacetin has not
produced the renal changes that have supposedly been found in man (Strimer and
Morin, 1975. This difficulty in proving that phenacetin was toxic was due to the
fact that some phenacetin was contained in a large number of analgesic prepara-
tionq but now that it has been taken out of Phensic since 1966 the reason for this
patient's liver and renal damage must be sought elsewhere. D'Arcy and Griffin
(1972) state that it is clear that there is an association between papillary necrosis
and heavy consumption of preparations containing not only phenacetin but also
salicylates. Salicylates cause renal irritations and cells, casts and albumin can
appear in the urine. Prescott (1968) has reviewed salicylate toxicity and has stated
that impaired renal function, obliguria and anuria with renal tubular necrosis
may occur with overdosage of salicylates. Nanra and Kincaid-Smith (1970)
reported that nearly half the rats fed with aspirins and aspirin-containing com-
pounds developed papillary necrosis in 20 weeks.
There is strong circumstantial evidence to suggest that this patient suffered renal
damage by prolonged ingestion of aspirin, and when this was discontinued the
blood urea reverted to normal although the radiological picture has not yet
returned. Her withhdrawal symptoms could be assumed to be due to the cessation
of the caffeine intake. It is difficult to know whether the liver damage was due to
salicylate or caffeine, but it returned to normal very quickly after stopping the
Phensic. The further precautions to be taken in this case would be to ensure that
this patient should not take any analgesic compound as further serious and indeed
fatal results could ensue.
This case is reported to draw attention to the dangers of prolonged ingestion
of a simple compound "Phensic", containing salicylates and caffeine.
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